Does Co-administration of Lactate to an Oral Glucose Tolerance Test Lower the Glucose Response?

Metabolic Syndrome Clinical Trial

Official title:

Does Co-administration of Lactate to an Oral Glucose Tolerance Test Lower the Glucose Response?

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06265337
• Other study ID #: LAMETA-OGTT
• Status: Not yet recruiting
• Phase: N/A
• Start date: February 2024
• Est. completion date: January 2025

Study information

• Verified date: February 2024
• Source: University of Aarhus
• Contact: Natasa brkovic Zubanovic
• Phone: 004561698000
• Email: natasa.bz[@]clin.au.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To investigate whether co-administration of lactate with a glucose load affects postprandial glucose levels/handling, gastrointestinal hormones, gastric emptying, and appetite sensations in individuals with pre-diabetes when compared to placebo. Hypothesis: Oral lactate administration improves/lowers glucose excursions following an oral glucose tolerance test (OGTT) by stimulating insulin secretion and delaying glucose absorption.

Description:

The participants will be instructed to avoid hard-to-moderate physical activity for 48 hours before each of the two trial days. They will be instructed to eat the same diet 72 hours before the two trial days at the screening visit and to register it in MyFood24 which is an electronic foodlog. Trial days: The two trial days will be completely alike, besides the interventions consisting of either: 1. Placebo in an OGTT (300 mL salt water, NaCl) =CTR, or 2. Lactate in an OGTT (300 mL lactate drink = 25 g D/L-lactate bound to Na) =LAC with a stable isotope glucose tracer (D2-glucose) added to each of the interventions to measure glucose uptake. 1500 mg of paracetamol will be added to measure ventricular emptying rate using the acetaminophen test. An H3-glucose tracer will be continuously infused to measure glucose turnover. Glucose tolerance and absorption together with hepatic glucose production and insulin secretion will be quantified using the oral minimal model. After this, the participant can lie in their bed. Blood samples will be collected continuously during the day. Appetite sensations will be measured by a visual analogue scale (VAS). After 4 hours the trial day is finished, and the participants can go home. They will be instructed to collect two fecal samples after each of the trial days, which will be analysed for fecal microbiota composition (16S rRNA gene sequencing and quantitative PCR) and fecal fermentation metabolite profiles by our collaborator Clarissa Schwab. Analyses Blood sample analyses will be made for the concentration of lactate, insulin, GLP-1, GIP, ghrelin, LEAP-2, glucagon, c-peptide, blood glucose, triglycerides, cholesterol, and other relevant metabolites and hormones. Supplementary ventricular emptying rate will be compared between CTR and LAC. [3H ]-glucose-tracer will be infused for six hours (bolus 12 mCi, infusion 0,12 mCi/min) to determine glucose metabolism. Statistics and power calculation We will use simple paired t-tests and two-way repeated measure ANOVA analyses for comparing the two groups. Based on a previous study we will need 12 individuals to detect a difference of 15% in integrated glucose concentrations and 40% in disposition index after the OGTT (α=0.05, β=0.80). This is similar to the effect size observed in studies investigating the treatment with a dipeptidyl peptidase-4 inhibitor (a weak insulin secretagogue).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 12
• Est. completion date: January 2025
• Est. primary completion date: January 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• >40 years
• Written and oral consent
• HbA1c 39-47 mmol/L

Exclusion Criteria:

• Medicine with an impact on blood glucose and glucose metabolism
• Newly started medicine (<3 months prior to the inclusion time)
• Medicine changes (<3 months prior to the inclusion time and planned changes during the trial)
• Affected screening blood sample as evaluated by PI
• Hba1c > 47
• Allergy to paracetamol
• Doesn't speak or understand Danish.
• Special diets

Related Conditions & MeSH terms

• Insulin Resistance
• Metabolic Syndrome
• PreDiabetes

Intervention

Dietary Supplement:
• Lactate
Lactate in an OGTT (300 mL lactate drink = 25 g D/L-lactate bound to Na) =LAC with a stable isotope glucose tracer (D2-glucose) added to measure glucose.

Other:
• Placebo
Placebo in an OGTT (300 mL salt water, NaCl) =CTR with a stable isotope glucose tracer (D2-glucose) added to measure glucose.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Aarhus

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in integrated glucose concentrations between CTR and LAC following an OGTT		0-240 minutes after the OGTT
Secondary	Difference in glucose absorption	Oral minimal model	0-240 minutes after the OGTT
Secondary	Difference in insulin sensitivity	Oral minimal model	0-240 minutes after the OGTT
Secondary	Difference in insulin secretion	Oral minimal model	0-240 minutes
Secondary	Difference in free fatty acids concentration		0-240 minutes after the OGTT
Secondary	Difference in ventricular emptying rate	Acetaminophen test	0-240 minutes after the OGTT
Secondary	Difference in subjective appetite sensation	VAS score	0-240 minutes after the intervention
Secondary	Difference in integrated GLP-1 concentrations		0-240 minutes after the intervention